Novartis Ag (NVS) Payables (2009 - 2025)

Novartis Ag (NVS) has 14 years of Payables data on file, last reported at $5.1 billion in Q4 2025.

• Quarterly Payables rose 1389.28% year-over-year to $5.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 billion (up 1389.28% YoY) and the FY2025 annual result came in at $5.1 billion, up 1389.28% from the prior year.
• Payables grew to $5.1 billion in Q4 2025 per NVS's latest filing, from $4.5 billion in the prior quarter.
• The five-year high for Payables was $6.5 billion in Q4 2021, with the low at -$290.0 million in Q3 2024.
• Average Payables over 5 years is $2.1 billion, with a median of $345.0 million recorded in 2024.
• Year-over-year, Payables slumped 2166.67% in 2022 and jumped 7967.65% in 2023.
• Novartis Ag's Payables stood at $6.5 billion in 2021, then dropped by 6.87% to $6.0 billion in 2022, then sank by 93.46% to $393.0 million in 2023, then declined by 12.21% to $345.0 million in 2024, then jumped by 1389.28% to $5.1 billion in 2025.
• Business Quant data shows NVS's Payables at $5.1 billion in Q4 2025, $4.5 billion in Q2 2025, and $345.0 million in Q4 2024.